BACKGROUND AND PURPOSE: Subarachnoid hemorrhage (SAH) pathophysiology involves neurovascular proteolysis and inflammation. How these 2 phenomena are related remains unclear. We hypothesize that matrix metalloproteinases (MMPs) mediate the depletion of anti-inflammatory plasma-type gelsolin (pGSN). METHODS: We enrolled 42 consecutive SAH subjects and sampled cerebrospinal fluid (CSF) and blood on post-SAH Days 2 to 3, 4 to 5, 6 to 7, and 10 to 14. Control subjects were 20 consecutive non-SAH hydrocephalus patients with lumbar drains. Enzyme-linked immunosorbent assay, Western blotting, and zymography were used to quantify pGSN and MMP-9. RESULTS: In CSF, pGSN was lower in SAH compared with control subjects on post-SAH Days 2 to 3 (P=0.0007), 4 to 5 (P=0.041), and 10 to 14 (P=0.007). In blood, pGSN decreased over time (P=0.001) and was lower in SAH compared with control subjects on post-SAH Days 4 to 5 (P=0.037), 6 to 7 (P=0.006), and 10 to 14 (P=0.006). Western blots demonstrated that SAH CSF had novel bands at 52 and 46 kDa, representing cleaved pGSN fragments. Gelatin zymography showed that CSF MMP-9 was elevated in SAH compared with control subjects. Higher CSF MMP-9 correlated with lower CSF pGSN on post-SAH Day 7 (r=-0.38; P=0.05). CONCLUSIONS: SAH is associated with decreased CSF and blood pGSN and elevated CSF MMP-9. Novel cleaved pGSN fragments are present in CSF of SAH subjects, consistent with pGSN cleavage by MMPs. Because pGSN is known to inhibit inflammatory mediators, these findings suggest that MMPs may reduce pGSN and exacerbate inflammation after SAH. Further studies are warranted to investigate the mechanisms underlying MMP-pGSN signaling in SAH.
BACKGROUND AND PURPOSE:Subarachnoid hemorrhage (SAH) pathophysiology involves neurovascular proteolysis and inflammation. How these 2 phenomena are related remains unclear. We hypothesize that matrix metalloproteinases (MMPs) mediate the depletion of anti-inflammatory plasma-type gelsolin (pGSN). METHODS: We enrolled 42 consecutive SAH subjects and sampled cerebrospinal fluid (CSF) and blood on post-SAH Days 2 to 3, 4 to 5, 6 to 7, and 10 to 14. Control subjects were 20 consecutive non-SAH hydrocephaluspatients with lumbar drains. Enzyme-linked immunosorbent assay, Western blotting, and zymography were used to quantify pGSN and MMP-9. RESULTS: In CSF, pGSN was lower in SAH compared with control subjects on post-SAH Days 2 to 3 (P=0.0007), 4 to 5 (P=0.041), and 10 to 14 (P=0.007). In blood, pGSN decreased over time (P=0.001) and was lower in SAH compared with control subjects on post-SAH Days 4 to 5 (P=0.037), 6 to 7 (P=0.006), and 10 to 14 (P=0.006). Western blots demonstrated that SAHCSF had novel bands at 52 and 46 kDa, representing cleaved pGSN fragments. Gelatin zymography showed that CSFMMP-9 was elevated in SAH compared with control subjects. Higher CSFMMP-9 correlated with lower CSFpGSN on post-SAH Day 7 (r=-0.38; P=0.05). CONCLUSIONS:SAH is associated with decreased CSF and blood pGSN and elevated CSFMMP-9. Novel cleaved pGSN fragments are present in CSF of SAH subjects, consistent with pGSN cleavage by MMPs. Because pGSN is known to inhibit inflammatory mediators, these findings suggest that MMPs may reduce pGSN and exacerbate inflammation after SAH. Further studies are warranted to investigate the mechanisms underlying MMP-pGSN signaling in SAH.
Authors: Anja Hviid Simonsen; Sara Bech; Inga Laursen; Lisette Salvesen; Kristian Winge; Gunhild Waldemar; Lene Werdelin; Jørgen Erik Nielsen; James Norton McGuire; Lena Elisabeth Hjermind Journal: J Neurosci Methods Date: 2010-06-25 Impact factor: 2.390
Authors: Alina Kułakowska; Nicholas J Ciccarelli; Qi Wen; Barbara Mroczko; Wiesław Drozdowski; Maciej Szmitkowski; Paul A Janmey; Robert Bucki Journal: BMC Neurol Date: 2010-11-01 Impact factor: 2.474
Authors: M Endres; K Fink; J Zhu; N E Stagliano; V Bondada; J W Geddes; T Azuma; M P Mattson; D J Kwiatkowski; M A Moskowitz Journal: J Clin Invest Date: 1999-02 Impact factor: 14.808
Authors: Ji Hae Seo; Shuzhen Guo; Josephine Lok; Deepti Navaratna; Michael J Whalen; Kyu-Won Kim; Eng H Lo Journal: Curr Pharm Des Date: 2012 Impact factor: 3.116
Authors: Antonio Segado-Arenas; Carmen Infante-Garcia; Isabel Benavente-Fernandez; Daniel Sanchez-Sotano; Juan Jose Ramos-Rodriguez; Almudena Alonso-Ojembarrena; Simon Lubian-Lopez; Monica Garcia-Alloza Journal: Mol Neurobiol Date: 2017-07-28 Impact factor: 5.590
Authors: Kevin Li-ChunHsieh; Stefan Schob; Matthias W G Zeller; Benjamin Pulli; Muhammad Ali; Cuihua Wang; Terry Ting-Yu Chiou; Yuk-Ming Tsang; Po-Shun Lee; Thomas P Stossel; John W Chen Journal: J Neuroimmunol Date: 2015-08-09 Impact factor: 3.478
Authors: Sanjaya Kuruppu; Sherry H-Y Chou; Steven K Feske; Sarah Suh; Iresha Hanchapola; Eng H Lo; Mingming Ning; A Ian Smith Journal: Mol Cell Proteomics Date: 2013-07-01 Impact factor: 5.911